Close Menu

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.

Qiagen will have an undisclosed number of layoffs as a result of the halted GeneReader development, though it plans to create new jobs elsewhere.

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."

The partners will codevelop software for both small and large variant detection and Illumina will create hardware-accelerated versions for its Dragen platform.

The firm disclosed to the state of California that it plans to lay off 42 employees in San Diego and 16 employees in Foster City.

Under the amended agreement, Illumina will pay PacBio $6 million each month until the end of this year and more if the deal is extended into 2020.

Using 350 human genomes from different populations, the two centers plan to develop a multi-genome reference sequence that is as complete as possible.

Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.

Get the latest news from Illumina, TRC, Diagnomics, Danaher, BioDiscovery and Abbot for the week of 9/13/19

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.